Kornimate/medical-research-clean huggingface dataset:
gastrointestinal bleeding and atmospheric pressure relationship

Conditions: Atmospheric Pressure; Adverse Effect; GastroIntestinal Bleeding

Summary: this study aims to investigate whether atmospheric pressure has an effect on upper gastrointestinal bleeding (ugib), which includes causes such as peptic ulcer disease, esophagitis, gastritis, gastrointestinal varices, mallory-weiss tears, and gastric cancer. the goal is to determine the impact of atmospheric pressure and gather information on its role in high-risk ugib.

ur study aims to investigate the potential effects of changes in atmospheric pressure on gastrointestinal bleeding, and if such effects exist, to review treatment adjustments based on weather forecasts for hypertensive patients to prevent potential hypertensive emergencies and enhance patient comfort. this research poses no risk to patients and is purely observational and clinical in nature. after initial evaluation upon presentation to the emergency department, patients will undergo routine emergency department monitoring for gastrointestinal bleeding, including physical examination, vital sign monitoring, evaluation of coagulation parameters, and hemoglobin levels. apart from routine tests, no additional invasive or non-invasive procedures will be performed by us. obtained data from patients and atmospheric pressure data will be analyzed and evaluated. results will be analyzed to determine any relation between gastrointestinal bleeding and atmospheric pressure changes

Eligibility criteria:
inclusion criteria: patients aged 18 and above patients presenting to the emergency department with complaints of gastrointestinal bleeding, whether active or resolved patients willing to participate in the study patients from central districts of ankara exclusion criteria: patients under the age of 18 pregnant individuals patients with a history of trauma at the time of admission patients declaring they are from a city other than ankara

Keywords: atmospheric pressure gastrointestinal bleeding emergency department
an open-label, multi-center, clinical study evaluating the effect of the nde l68 stablefit® punctal plug on the tear lake

Conditions: Dry Eye Syndromes

Summary: to evaluate the effect of the nde l68 stablefit® punctal plug on the tear lake.

this is a non-significant risk (nsr) medical device, multi-center, open-label clinical study. each study subject that qualifies at the baseline visit will receive an nde l68 stablefit® punctal plug in the lower punctum in one of their eyes. all study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion.

Eligibility criteria:
inclusion criteria: 1. a male or female subject, 18 years of age or older, in good general health at the time of the baseline examination, who may or may not have a mild to moderate dry eye condition 2. a subject must be able to read, comprehend and be willing to give hipaa authorization and informed consent 3. a subject must be willing to have a punctal plug inserted in the lower punctum of one of their eyes 4. a subject must be willing to comply with all study instructions, agree to make all office appointments, and complete the entire course of the study exclusion criteria: 1. a subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in the planned study eye 2. a subject with a history of intolerance to punctal plugs 3. a subject with structural lid abnormalities (e.g., ectropion, entropion) in the planned study eye 4. a subject with any clinically significant lid, conjunctival or corneal findings in the planned study eye at the baseline visit 5. a subject with a severe dry eye condition 6. a subject experiencing epiphora in the planned study eye 7. a subject experiencing any clinically significant ocular pain or discomfort in or around either eye at the baseline visit
cranberry-lingonberry juice started during acute infection in prevention of urinary tract infections in children

Conditions: Urinary Tract Infection; Pyelonephritis; Cystitis

Summary: cranberry and cranberry-lingonberry juice prevented urinary tract infections in children and in adults in our earlier clinical trials. the preventive effect was, however, observed late in the follow-up and the next recurrence was not prevented in children. the investigators hypothesize that cranberry-lingonberry juice should be started already during the antimicrobial treatment of acute urinary tract infection in order to maximize the preventive efficacy of the juice. in addition, the investigators aim to find the explanation for the efficacy of cranberry-lingonberry juice by analyzing the concomitant changes in the chemical composition of urine and feces as well as the changes of gut microbiota.


Eligibility criteria:
inclusion criteria: * recent confirmed urinary tract infection, diagnosed in oulu university hospital or oulu health care center * age 1-16 years exclusion criteria: * continuous antimicrobial prophylaxis * age \ 16 years * severe congenital kidney or other urinary tract anomaly in ultrasound
effects of remimazolam on the intraoperative hemodynamics in bypass surgery

Conditions: Intraoperative Hypotension

Summary: this study is a randomized, controlled trial. a total of 72 patients will be randomized to receive remimazolam anesthesia or balanced anesthesia (propofol + desflurane) during extracranial-intracranial bypass surgery.


Eligibility criteria:
inclusion criteria: * patients who undergo elective extracranial-intracranial bypass surgery * american society of anesthesiologists grade 1,2,3 * age \> 18 years old exclusion criteria: * refuse to participate to the study * american society of anesthesiologists grade 4 * body mass index \ 35 kg/m2 * allergic history of benzodiazepine * pregnant * acute narrow-angle glaucoma * shock or coma * acute alcohol addicted * obstructive sleep apnea * dependency on alcohol or drug * severe acute respiratory insufficiency * hypersensitivity to dextran 40
covid-19 patient cohort: retinal damage in non-invasive retinal imaging (octa)

Conditions: Covid19; Retina Injury

Summary: the objective of this research is to build a collection of non-invasive retinal imaging (oct and octa) in order to investigate the incidence and impact of retinal damage in patients who have or have had covid-19.

this monocentric study is aimed at 3 types of patients: * those who have been hospitalized for covid-19 during the epidemic * newly infected and diagnosed patients covid-19 * those with paucisymptomatic covid-19 who did not require hospitalisation at the patient's inclusion, an ophthalmologic assessment will be performed including : * visual acuity, * sd-oct + multicolor, * oct-a, * color retinography, fundus examination, optical coherence tomography (oct) and optical coherence tomography angiography (octa) in all covid-19 patients may detect retinal lesions. in addition, if a correlation is demonstrated between clinical and paraclinical parameters and between disease severity and retinal vascular damage in non-invasive imaging (oct and octa), this would allow a better understanding of the pathophysiology of the disease, as well as factors that may influence disease severity and the mechanisms potentially responsible for the observed disorders.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * diagnosis of covid-19 proven on rt-pcr, antigenic test or chest ct scan * affiliation to the general social security system * a consent signed by the patient exclusion criteria: - refusal of patient participation

Keywords: oct-a oct
inert gas rebreathing in ventilated patients

Conditions: Sepsis; Respiratory Failure; Heart Failure; Renal Failure

Summary: measuring hemodynamic parameters in ventilated patients is important yet still complicated to perform. inert gas rebreathing (igr) showed promising results when being compared to other invasive as well as non-invasive techniques for the measurement of cardiac output. the aim of our study is to evaluate the feasibility of igr in ventilated patients.


Eligibility criteria:
inclusion criteria: * age 18 - 80 years * mechanically ventilated patient * existing picco arterial line exclusion criteria: * fio2 \> 60% (fraction of inspired oxygen) * peep \> 10 mmhg (positive end-expiratory pressure) * so2 \< 90% (oxygen saturation ) * systolic blood pressure \< 90 mmhg * heart rate \> 150 bpm * aprv (airway pressure release ventilation) * icd (implantable cardioverter defibrillator) / pace maker * \[ anaesthetic conserving device (anaconda) \]

Keywords: cardiac output mechanical ventilation inert gas rebreathing pulse contour analysis
the influence of an e-learning program on recognition of actinic keratosis

Conditions: Actinic Keratoses; E-learning; Dermatology

Summary: the evaluation on the diagnostic accuracy of actinic keratosis recognition by general practitioners before and after participation on an e-learning program.

actinic keratosis is defined as the most frequent common intra-epithelial neoplasm in the caucasian population, with an increasing prevalence. if left untreated, actinic keratosis has the potency to develop into a cutaneous squamous-cell carcinoma. treatment of actinic keratosis is aimed at both lesion reduction and to prevent malignant transformation. to achieve treatment adherence for patients, it is necessary to raise physician awareness about actinic keratosis. this study primarily aimed to investigate whether the sensitivity of establishing a correct actinic keratosis diagnosis by general practitioners (in training) would increase after participating in an e-learning program about the recognition of actinic keratosis. this was achieved by comparing the results of a pre- and post-test completed by general practitioners which was incorporated in the e-learning program.

Eligibility criteria:
inclusion criteria: * general practitioner in the netherlands * access to e-learning module via phone/computer/tablet * knowledge of the dutch language exclusion criteria: * no knowledge of the dutch language * different specialists than general practitioner
study to evaluate syn115 in parkinson's disease

Conditions: Parkinson's Disease

Summary: this is an exploratory study to evaluate if syn115 has an effect on parkinson's disease as measured by clinical symptoms and brain images using magnetic resonance imaging (mri) when a function test is administered.

this is a randomized, double-blind, placebo-controlled, two-way crossover study in which each patient will act as their own control. each patient enrolled will receive both syn115 (20 mg or 60 mg) and placebo separated by a minimum of one week washout between periods. an adaptive design will be used to determine if syn115 elicits effects relevant to pd in the fewest number of patients by performing interim analyses in successive cohorts of patients receiving 60 or 20 mg.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease * hoen and yahr stage 1-3 * on stable dose of anti-parkinsons treatment for 30 days prior to screening * age 40 to 75 years * sign an irb approved informed consent * men and women agree to use adequate birth control * ecg measurements are within normal limits * able to understand study requirements exclusion criteria: * secondary parkinson's (drug induced or post stroke) * received treatment with other investigational drug 30 days prior to study entry * using disallowed medications * significant neurological illness other than parkinson's * iq less than 70 on iq test * mmse score \< or = 23 * history of psychosis or on anti-psychotic medication * current serious medical illness * history of substance abuse * history of head injury with loss of consciousness * history of brain surgery * contraindications to mri like claustrophobia, metal implants or other implantable devices * abnormal liver function tests and/or hepatitis or cholangitis * gilberts disease * pregnant or nursing * known hypersensitivity to syn115
pilot study of the human metagenome in metabolic diseases

Conditions: Obesity; Sarcopenia; Sarcopenic Obesity; Chronic Inflammation; Metabolic Syndrome

Summary: this is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia. recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing. we hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.

the human metagenome comprises all nucleotide sequences isolated from all organisms living on and within an individual and has been shown to have significant alterations in relation to certain diseased states related to chronic inflammation, such as obesity and sarcopenia. the gut bacteriome, and more recently the virome, has been shown to be significantly correlated with the obese phenotype, while gut microbiome dysbiosis is known to occur in individuals with sarcopenia. clinically, there is an unmet clinical need to better personalize the treatment of patients with metabolic disorders such as obesity and metabolic syndrome, and patients suffering from sarcopenia and frailty as a result of aging. however, the literature regarding the metagenomic signatures associated with these disorders, in particular the non-bacteriome species, bacterial metabolites, and their relationship with host metabolism, were scarce. thus we hypothesize, that the human metagenome and metabolome, may play a role in influencing chronic inflammatory disorders related to metabolic disorders, such as obesity and diseases related to aging like sarcopenia and aging. this is a cohort study, involving metagenomic sequencing and metabolomic analysis, of patients metagenome and metabolome, in various diseased states. a cohort of healthy control patients without obesity or sarcopenia will also be recruited. samples collected will include fecal, salivary, serum, urine, mucosal samples for metagenomic sequencing and metabolomic testing.

Eligibility criteria:
inclusion criteria (obese cohort): * obese (bmi\>27.5kg/m2) inclusion criteria (sarcopenic cohort): * sarcopenic patients, defined as 1) low handgrip strength (\<26 for males; \<18kg for females), and/or low gait speed (\<0.8m/s) and low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females) inclusion criteria (control cohort): - healthy subjects without sarcopenia, and not obese (bmi\<27.5kg/m2) exclusion criteria: * no informed consent * presence of intestinal stoma, hence inability to collect fecal samples

Keywords: obesity sarcopenia metabolic syndrome metagenomics metabolomics
stop af first post-approval study

Conditions: Paroxysmal Atrial Fibrillation

Summary: the stop af first pas is a prospective, global, multi-center, observational trial.

the stop af first post approval study (pas) is a sub-study to the cryo global registry. the stop af first pas is a prospective, global, multi-center, observational trial. the purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal af population treated with arctic front™ and freezor™ max families of cardiac cryoablation catheters (hereafter referred to as arctic front™ cardiac cryoablation catheter system) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. this pas is a condition of the pre-market approval order (p100010/s110) by the u.s. food and drug administration.

Eligibility criteria:
inclusion criteria: * subject has been diagnosed with symptomatic paroxysmal af * subject is ≥ 18 years of age or minimum age as required by local regulations * planned pulmonary vein isolation (pvi) procedure using the commercially available arctic front™ cardiac cryoablation catheter system. * willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements exclusion criteria: history of af treatment with a class i or iii antiarrhythmic drug, including sotalol, with the intention to prevent an af recurrence1 . subjects under the following conditions may be included in the study: 1. temporary treatment with a class i or iii aad (treatment at a therapeutic dose for a period of \<4 weeks prior to the index pvi procedure) 2. recent treatment with a class i or iii aad (within 6 months of the index pvi procedure) at a dose below therapeutic threshold according to the aha/acc/hrs guideline for the management of patients with atrial fibrillation 3. a subject who has received a chemical cardioversion may be included in the study. this includes a chemical cardioversion prior to enrollment and between enrollment and ablation. * subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (cti) ablation for afl) * subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager * subject with exclusion criteria required by local law
long-term quality of life among survivors of sepsis in china assessed by eq-5d

Conditions: Sepsis

Summary: sepsis is a common critical illness in intensive care unit (icu). with the continuous progress of severe medicine, the mortality rate of icu hospitalization for sepsis has decreased, but the long-term prognosis is not satisfied. due to the high long-term mortality, poor physical and mental health and cognitive impairment, the long-term quality of life decreases greatly, putting great burden on the family and society. therefore, it is of great significance to understand the epidemiology and risk factors of the long-term prognosis of sepsis and find out how to improve the prognosis .

sepsis is a clinical syndrome in which the body's host response to uncontrolled infection leads to life-threatening organ dysfunction. in recent years, with the continuous improvement of the early diagnosis ability of sepsis, the deepening of the understanding of pathophysiology, and the continuous updating of treatment, the hospital mortality rate of sepsis has decreased significantly. however, studies have shown that the prevalence of sepsis is still increasing year by year, and the number of deaths due to sepsis is increasing. sepsis is the main cause of death in icu patients. although the mortality rate of patients with sepsis is significantly reduced, the increasing survival of patients with long-term outcome is not satisfied. all studies have shown that patients with sepsis have a high long-term mortality, and the long-term physiological, psychological, and cognitive function levels are reduced, which increases the economic burden and mental burden of the family and society. the increasing number of discharges has been considered a potential public health threat. in recent years, more and more researchers begin to pay attention to the long-term outcome of sepsis survivors. but compared with other acute or severe diseases, such as stroke, cancer, sepsis survivors has not been paid enough attention. therefore, all stages of treatment and rehabilitation of sepsis require extensive social attention. continuous research and input are needed to explore predicting factors and effective interventions to improve the outcome and help patients and their families return to normal life,to reduce the social burden.

Eligibility criteria:
inclusion criteria: * survivors in the prior study (epidemiology survey of chinese sepsis patients) exclusion criteria: * : patients who are unwilling to answer or lose their interviews
effect of the autonomic nervous system on the outcomes of pulsed field ablation to treat atrial fibrillation

Conditions: Atrial Fibrillation

Summary: pulmonary vein (pv) isolation is considered the therapeutic strategy of choice to maintain sinus rhythm (sr) in symptomatic patients with atrial fibrillation (af). the most commonly used energy modality is radiofrequency (rf). however, this type of energy presents notable challenges, such as its lack of selectivity for myocardial tissue, which increases the risk of serious complications such as atrioesophageal fistula, pv stenosis, and vagus nerve injuries. in this context, pv isolation using pulsed field ablation (pfa) emerges as a promising alternative due to its greater myocardial selectivity. however, this selectivity presents additional challenges. preliminary studies indicate that pfa may not damage the autonomic nervous system (ans) involved in the initiation and maintenance of af in certain patients, although stronger evidence is needed to support this claim. the investigators propose to carry out a single-center clinical trial, although with the possibility in the future of including other centers. patients will be randomized to three research groups: pv isolation with rf, pv isolation with pfa, and pv isolation combining pfa and rf (using rf on the anterior wall and pfa on the posterior wall). this assignment will be open to the operator who performs the procedure, but blind for the researcher responsible for monitoring and for the data analyst. the objective is to compare the impact of different energy sources during pv isolation on the ability to produce a permanent alteration in the ans. the hypothesis is that combined pf isolation will be capable of producing a permanent alteration of autonomic function parameters superior to ablation using exclusive pfa.


Eligibility criteria:
inclusion criteria: - patients with a diagnosis of paroxysmal atrial fibrillation, referred to our center for pulmonary vein isolation, who are willing and able to sign the informed consent. exclusion criteria: * patients with permanent atrial fibrillation. * patients with previous pulmonary vein isolation procedure. * patients with pacemakers, or with a diagnosis of atrioventricular block or sinus dysfunction. * patients who show their refusal to participate in the registry, or are unable to understand the informed consent. * patients under 18 years of age. * pregnant.

Keywords: atrial fibrillation pulmonary vein isolation pulsed field ablation